NICE

News

Janssen J&J Johnson and Johnson pharmaceutical companies

NICE makes J&J's Tremfya more accessible in England and Wale...

NICE has updated its recommendations for NHS use of Johnson & Johnson's IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible fo

News

BMS' Opdivo gets NHS use as adjuvant bladder cancer therapy

NICE has recommended routine use of Bristol-Myers Squibb's Opdivo for the adjuvant treatment of some patients with urothelial carcinoma (UC), the most common form of bladder cancer.

News

Lilly's Verzenios gets NICE blessing for early-stage breast ...

Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli Lilly's Verzenios, after new guidance from NICE backed use of the drug after surge

Market Access

Questions linger as England’s Innovative Medicines Fund kick...

In part one of this two-article series on the latest on England’s Innovative Medic

News

3D Illustration Concept of Human Urinary System Kidneys Anatomy

Hansa gets NICE okay for Idefirix in kidney transplant patie...

Sweden's Hansa Biopharma has claimed a positive opinion from NICE for Idefirix, which becomes the first drug cleared for NHS use in a group of kidney transplant patients for whom finding a

News

NICE backs Astellas' oral therapy Evrenzo for anaemia in kid...

Astellas' oral HIF-PH inhibitor Evrenzo has become the first drug in the class to be recommended for routine NHS use as a treatment for anaemia in chronic kidney disease (CKD), ahead of riv

NICE makes J&J's Tremfya more accessible in England and Wale...

BMS' Opdivo gets NHS use as adjuvant bladder cancer therapy

Lilly's Verzenios gets NICE blessing for early-stage breast ...

Questions linger as England’s Innovative Medicines Fund kick...

Hansa gets NICE okay for Idefirix in kidney transplant patie...

NICE backs Astellas' oral therapy Evrenzo for anaemia in kid...

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

NICE

Editor's Picks